Eczema drug may lift mood: new study targets anxiety and depression
NCT ID NCT07467564
First seen Mar 27, 2026 · Last updated May 14, 2026 · Updated 5 times
Summary
This study is testing whether dupilumab, a medication already used for moderate-to-severe atopic dermatitis (eczema), can also help reduce anxiety and depression symptoms. About 184 participants in Gulf countries who have eczema and signs of anxiety or depression will be observed for 6 months after starting dupilumab. The goal is to see if treating the skin condition improves mental health and quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NMC Specialty Hospital LTD
RECRUITINGAbu Dhabi, United Arab Emirates
-
Saudi Medical Services (Medical Fakeeh)
RECRUITINGJeddah, 21331, Saudi Arabia
Conditions
Explore the condition pages connected to this study.